Eli Lilly CEO says Medicare coverage of obesity drugs could ‘change the game’ for upcoming pill launch  CNBC Recent Trends in GLP-1 Use and Spending in

PULSE POINTS WHAT HAPPENED: Eli Lilly announced plans to invest over $3.5 billion to build a manufacturing plant in Pennsylvania’s Lehigh Valley to produce next-generation

MORE women than men were handed fat jab medicines on the NHS last year. Stats for England show 310,300 got GLP-1 slimming injections from their

Participating Medicare Part D plans can officially begin covering weight-loss treatment in 2027.  The initiative falls under CMS’ voluntary “Better Approaches to Lifestyle and Nutrition

As more and more of our favorite stars step out with newly slimmed-down physiques, one of the first questions many can’t help but ask is,

There were many reports today stating 29% of employees would consider changing jobs if a new role covered GLP-1 meds. Wondering if it’s something that

EU regulators have refused to greenlight Eli Lilly’s weight loss drug Mounjaro as a treatment for a type of heart failure, while giving the go-ahead

Kayshild is recommended for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced liver fibrosis. Medscape News Europe

The MHRA has updated safety information for GLP-1 weight-loss and diabetes drugs after rare reports of necrotising and fatal pancreatitis. Medscape News UK

This Medical News article discusses clinical trial data for weight-loss medications, in both injectable and pill formations, that are currently under review with US Food

Although bariatric surgery was associated with more evident changes, research found that treatment with glucagon-like peptide-1 (GLP-1) medications was also associated with sustained fat loss

The US Food and Drug Administration (FDA) requested that drug application holders remove suicidal ideation and behavior warnings from glucagon-like peptide-1 (GLP-1) receptor agonists.

IJMS, Vol. 27, Pages 1409: Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes International Journal of

Mounjaro significantly reduced hospitalizations in adults with obesity and symptomatic chronic heart failure with preserved ejection fraction. Medscape News Europe

(NaturalNews) IntroductionA seismic shift in American health culture is being violently undone in courtrooms across the nation. The blockbuster GLP-1 weight-loss …

Post Content

“No one says, ‘Here’s your GLP-1, by the way, you might get an eating disorder.’”

Health chiefs have warned that GLP-1 medication increases risk of developing severe inflammation of the pancreas – which can be fatal.

‘My Colon Literally Blew Up’: Thousands Sue Over GLP-1 Weight Loss Drug Side Effects A growing wave of lawsuits is challenging the safety warnings accompanying

(MedPage Today) — GLP-1 receptor agonist use was tied to a lower risk of recurrent major adverse limb events (MALEs) in people with diabetes compared

Beyond the brand names: Everything you need to know about Ozempic and other GPL-1 medications  nypost.com GLP-1 drugs don’t work for everyone. But personalized obesity care

(MedPage Today) — GLP-1 receptor agonists and SGLT2 inhibitors were associated with lower risks for liver-related events and hepatocellular carcinoma (HCC) in type 2 diabetes

Poison control calls involving GLP-1 medications like semaglutide and tirzepatide have dramatically risen in recent years.

A renowned physician-scientist says treatment is not one-size-fits-all.

The complaints number over 4,400, a fraction of the more than 31 million people taking the weight-loss drugs

THURSDAY, Jan. 29, 2026 — Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with reduced postoperative revision following functional endoscopic sinus surgery (FESS)

At least 3,000 patients have filed lawsuits against the companies behind GLP-1 weight loss drugs, alleging severe health risks, including blindness. NewsNation’s Brooke Shafer has

Some patients have pointed to severe undisclosed side effects, including blindness, loss of brain function and organ damage.

The desire for smaller portions and fewer junk foods is affecting what the food industry is selling us.

Here’s What Happens When You Stop Taking Ozempic and Wegovy – WSJ  The Wall Street Journal Hard truth about what happens when you stop weight loss

The initiation of GLP-1 receptor agonists is associated with modest shifts away from ultraprocessed foods and toward items with fewer calories and smaller amounts of

PTER (phosphotriesterase-related) is an amidohydrolase that mediates catabolism of the anorexigenic taurine metabolite N-acetyltaurine. However, the structural basis of PTER ligand binding and catalysis remains

A study linking statins, the microbiome, and blood sugar control doesn’t change clinical practice The post Navigating the complex relationship between statins, GLP-1, and glycemic

Join the American Heart Association for an insightful session with Dr. Clyde Yancy and Dr. Dhruv Kazi. Recent clinical trials demonstrate the efficacy of incretin-based

In my column last Monday, I wrote about how to make better New Year’s resolutions—ones that are less likely to flop, but that are also

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached a settlement over a trading